1-4 of 4
Jason Melear, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, DO, MS, William Bensinger, MD, John M Burke, Mohit Narang, MD, Don Stevens, MD, Sriya W. Gunawardena, MD, Yana Lutska, PharmD, Keqin Qi, PhD, Jon Ukropec, PhD, Ming Qi, MD PhD, Thomas Lin, MD PhD, Robert M Rifkin, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 152.
https://doi.org/10.1182/blood-2018-152
Published: 2018
Journal Articles

Results of an Interim Safety Analysis of a Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Previously Untreated and Relapsed Patients (Pts) with Multiple Myeloma (MM)

Habte Yimer, MD, Jason Melear, MD, Edward Faber, William I. Bensinger, MD, John M Burke, MD, Sriya Gunawardena, MD, Murphy Sean, Hollee Parros, Yana Lutska, Mohamed Darif, PhD, Anil Londhe, PhD, Ming Qi, Jon Ukropec, Thomas Lin, Robert M. Rifkin, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1839.
https://doi.org/10.1182/blood.V130.Suppl_1.1839.1839
Published: 2017
Journal Articles

MAGNIFY: Phase IIIb Randomized Study of Lenalidomide Plus Rituximab (R 2 ) Followed By Lenalidomide Vs. Rituximab Maintenance in Subjects with Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma

David J. Andorsky, MD, Abdulraheem Yacoub, MD, Jacob D. Bitran, MD, Jason Melear, MD, Heather D. Brooks, MD BS, BA, Kenneth A. Foon, MD, Syed Rizvi, MD, Mary Llorente, Jiahui Li, PhD, Jeff P. Sharman, MD
Journal: Blood
Blood (2016) 128 (22): 1798.
https://doi.org/10.1182/blood.V128.22.1798.1798
Published: 2016
Journal Articles

Ublituximab (TG-1101), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with Ibrutinib Is Highly Active in Patients with Relapsed and/or Refractory Mantle Cell Lymphoma; Results of a Phase II Trial

Kathryn Kolibaba, MD, John M. Burke, MD, Heather D. Brooks, MD BS, BA, Daruka Mahadevan, MD PhD, Jason Melear, MD, Charles M. Farber, MD PhD, Suzanne R. Fanning, DO, Marshall T. Schreeder, MD, Ralph V. Boccia, MD, Peter Sportelli, Hari P. Miskin, MS, Michael S. Weiss, Jeff P. Sharman, MD
Journal: Blood
Blood (2015) 126 (23): 3980.
https://doi.org/10.1182/blood.V126.23.3980.3980
Published: 2015